Search

Author/Creator Cullberg, Marie

1. Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. Issue 2 (28th September 2021)

Authors:
Voronova, Veronika; Cullberg, Marie; Delff, Philip; Parkinson, Joanna; Dota, Corina; Schiavon, Gaia; Maroj, Brijesh; Rekić, Dinko; Cheung, S. Y. Amy
Journal:
British journal of clinical pharmacology
Issue:
Volume 88:Issue 2(2022)
Page Start:
858
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Issue 10 (October 2016)

Authors:
O'Byrne, Paul M; Metev, Hristo; Puu, Margareta; Richter, Kai; Keen, Christina; Uddin, Mohib; Larsson, Bengt; Cullberg, Marie; Nair, Parameswaran
Journal:
Lancet
Issue:
Volume 4:Issue 10(2016)
Page Start:
797
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. In Silico Predictions and In Vivo Results of Drug–Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate. Issue 5 (23rd March 2016)

Authors:
Johansson, Susanne; Löfberg, Boel; Aunes, Maria; Lunde, Helen; Frison, Lars; Edvardsson, Nils; Cullberg, Marie
Journal:
Clinical pharmacology in drug development
Issue:
Volume 5:Issue 5(2016:Sep./Oct.)
Page Start:
364
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗